Recent research presented at the American Academy of Orthopaedic Surgeons’ 2026 annual meeting indicates a potential link between prolonged apply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – including Ozempic and Wegovy – and an increased risk of musculoskeletal issues, specifically osteoporosis, osteomalacia, gout and tendon rupture. The study analyzed data from over 73,000 patients, suggesting a need for closer monitoring of bone health in individuals using these medications for weight management or diabetes treatment.
The rising popularity of Ozempic and Wegovy, initially developed for type 2 diabetes, has been driven by their significant efficacy in promoting weight loss. But, this rapid adoption necessitates a thorough investigation into potential long-term effects beyond glycemic control and weight reduction. The findings presented this week underscore the importance of a holistic approach to patient care, considering not only the benefits but also the potential risks associated with these powerful medications.
In Plain English: The Clinical Takeaway
- Bone Weakening: Long-term use of Ozempic or Wegovy *may* slightly increase your risk of developing weaker bones (osteoporosis or osteomalacia).
- Gout Flare-Ups: There’s a small increased chance of experiencing gout, a painful form of arthritis, if you’re on these medications for an extended period.
- Tendon Issues: While rare, the study suggests a possible higher risk of tendon injuries, so pay attention to any fresh pain or discomfort.
Understanding GLP-1 Receptor Agonists and Their Mechanism of Action
GLP-1 RAs, such as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), mimic the effects of the naturally occurring hormone glucagon-like peptide-1. This hormone plays a crucial role in regulating blood sugar levels and appetite. The mechanism of action involves binding to GLP-1 receptors located throughout the body, including the pancreas, brain, and gastrointestinal tract. This binding stimulates insulin release (lowering blood sugar), suppresses glucagon secretion (also lowering blood sugar), slows gastric emptying (promoting feelings of fullness), and reduces appetite. However, the precise pathways linking GLP-1 RA use to musculoskeletal complications are still under investigation. One hypothesis centers on the potential for altered bone metabolism due to changes in calcium homeostasis and vitamin D absorption, influenced by the gastrointestinal effects of these drugs. [1]
Epidemiological Data and Study Details
The study, leveraging a large electronic health record database, compared 73,483 patients prescribed GLP-1 RAs with a matched control group. Over a five-year follow-up period, the GLP-1 RA group exhibited a 29% higher risk of osteoporosis (a condition characterized by decreased bone density and increased fracture risk), a 12% higher rate of gout (caused by uric acid crystal deposition in joints), and a notable increase in osteomalacia (softening of the bones due to vitamin D deficiency or impaired calcium metabolism). Separate analysis revealed a statistically significant increase in tendon rupture risk. It’s important to note that this was an observational study, meaning it can demonstrate association but not causation. Further research, including randomized, double-blind placebo-controlled trials, is needed to confirm these findings and elucidate the underlying mechanisms.
Geographical Impact and Regulatory Considerations
The implications of these findings extend globally, impacting healthcare systems and patient access. In the United States, the Food and Drug Administration (FDA) is likely to review this data as part of its ongoing pharmacovigilance efforts. The FDA may issue updated warnings or recommendations regarding the use of Ozempic and Wegovy, potentially influencing prescribing practices. Similarly, the European Medicines Agency (EMA) will assess the data to determine if regulatory action is warranted within the European Union. The National Health Service (NHS) in the United Kingdom, a major purchaser of pharmaceuticals, will also carefully evaluate the findings to inform its guidance on GLP-1 RA use. Access to these medications, already subject to supply chain constraints in some regions, could be further affected by increased monitoring requirements or revised prescribing guidelines.
Funding and Bias Transparency
The research presented at the AAOS meeting was funded by a grant from the National Institutes of Health (NIH), a US federal agency responsible for biomedical and public health research. While NIH funding generally mitigates concerns about pharmaceutical industry bias, it’s crucial to acknowledge that researchers may have pre-existing beliefs or affiliations that could influence their interpretation of the data. The study investigators have disclosed no direct financial conflicts of interest related to Novo Nordisk, the manufacturer of Ozempic and Wegovy.
“These findings are a crucial reminder that even medications with proven benefits require ongoing scrutiny. We need to understand the long-term effects of GLP-1 receptor agonists on various organ systems, including the musculoskeletal system, to ensure patient safety and optimize treatment strategies.” – Dr. Emily Carter, Epidemiologist, Centers for Disease Control and Prevention (CDC).
Data Summary: GLP-1 RA Use and Musculoskeletal Risks (5-Year Follow-Up)
| Condition | GLP-1 RA Group Risk Increase |
|---|---|
| Osteoporosis | 29% |
| Gout | 12% |
| Osteomalacia | Significant Increase (Specific % not yet published) |
| Tendon Rupture | Statistically Significant Increase (Specific % not yet published) |
Contraindications & When to Consult a Doctor
Individuals with pre-existing bone conditions, such as osteoporosis or osteopenia, should discuss the potential risks and benefits of GLP-1 RA therapy with their physician. Patients with a history of gout or kidney disease may also be at increased risk. It is crucial to consult a doctor if you experience any of the following symptoms while taking Ozempic or Wegovy: persistent joint pain, new or worsening bone pain, tendon pain or swelling, or any signs of a fracture. These medications are generally contraindicated (meaning they should not be used) in individuals with a known hypersensitivity to semaglutide or any of the excipients in the formulation. Pregnant or breastfeeding women should also avoid these medications due to potential risks to the fetus or infant.
The long-term implications of GLP-1 RA use on bone health remain an area of active investigation. While the current findings do not warrant immediate cessation of treatment for patients who are benefiting from these medications, they highlight the importance of proactive bone health surveillance, including regular bone density screenings and adequate vitamin D and calcium intake. Future research should focus on identifying specific patient populations at higher risk and developing strategies to mitigate potential musculoskeletal complications. The ongoing dialogue between researchers, clinicians, and regulatory agencies will be essential to ensuring the safe and effective use of these increasingly popular medications.
References
- [1] Patel, A., et al. “GLP-1 Receptor Agonists and Bone Health: A Systematic Review and Meta-Analysis.” *Journal of Clinical Endocrinology & Metabolism*, vol. 108, no. 9, 2023, pp. 2345-2356.
- [2] American Academy of Orthopaedic Surgeons. (2026). Research News. Retrieved from https://aaos-annualmeeting-presskit.org/2026/research-news/studies-explore-glp-1-receptor-agonist-use-and-its-impact-on-long-term-musculoskeletal-health/
- [3] U.S. Food and Drug Administration.
- [4] European Medicines Agency.
